inv-102
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 30, 2022 (NCT05586152)
Timeline
Indications
Mechanism of action
- Cellular tumor antigen p53ACTIVATOR
TP53 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06599684 | Phase 2 | Sep 7, 2024 | Invirsa, Inc. |
| NCT06370039 | Phase 2 | Mar 27, 2024 | Invirsa, Inc. |
| NCT05636228 | Phase 2 | Apr 30, 2023 | Department of Health and Human Services, Invirsa, Inc. |
| NCT05586152 | Phase 1/Phase 2 (Phase 2) | Aug 30, 2022 | Department of Health and Human Services, Invirsa, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Invirsa, Inc. | For profit | 4 | 4 | 1 | 2022 |
| Department of Health and Human Services | Government | 2 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1